Aura Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Aura Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $270.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aura Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $270.8K Trade | TransData Nexus

Aura Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $270.8K Total Trade · DGFT Verified

Aura Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $270.8K across 2 products in 2 therapeutic categories. Based on 19 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ornidazole ($222.1K), Biotin ($48.6K), .

Aura Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Aura Pharmaceuticals Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Aura Pharmaceuticals Private Limited? — Company Overview & Market Position

Aura Pharmaceuticals Private Limited (APPL) is a privately held pharmaceutical company established on December 17, 2009, in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24239MH2009PTC197919. APPL specializes in the manufacturing, marketing, and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's authorized and paid-up capital stands at ₹5.13 million, reflecting its financial foundation.

As of the latest available data, APPL employs approximately 76 professionals. The company's registered office is located at 306, A - Wing, Hari Om Plaza, M. G. Road, Borivali (East), Mumbai, Maharashtra, 400066. APPL's annual turnover is around ₹500 million, indicating a significant presence in the Indian pharmaceutical market.

What Does Aura Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ornidazole$222.1K 2Biotin

Product Portfolio — Top 2 by Export Value

Aura Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ornidazole	Advanced Antibiotics	$222.1K	14	1.3%	7
2	Biotin	Vitamins & Supplements	$48.6K	5	3.2%	3

Aura Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $270.8K. The top category is Advanced Antibiotics (82.0% of portfolio), followed by Vitamins & Supplements (18.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Aura Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

APPL operates manufacturing facilities in Mumbai, Maharashtra, India. While specific details regarding plant capacities and specializations are not publicly disclosed, the company is known for producing a range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The facilities adhere to industry standards to ensure the quality and safety of their products.

3Key Leadership

The leadership team at APPL comprises several directors who oversee the company's operations:

Sultanali Juma Mulani
Suraj Mangalathu Viswanadhan
Santosh Francis Dsouza
Aspak Amirbhai Mulani
Hamza Abbas Ali Sadikot

These individuals bring diverse expertise to the company, contributing to its strategic direction and growth.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Aura Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

APPL's export activities are primarily focused on African countries, including the Democratic Republic of Congo, Angola, and Benin. The company is also exploring expansion into other African nations such as Sierra Leone, Namibia, Mozambique, and Zambia, as well as Far East countries like Vietnam and Cambodia, and regions like Russia, Ukraine, and other CIS countries.

2Emerging Markets

APPL's strategic expansion into emerging markets, particularly in Africa and Southeast Asia, is facilitated by its commitment to quality and competitive pricing. The company's adherence to international standards positions it to meet the regulatory requirements of these regions, enhancing its market penetration.

3Geographic Strategy

APPL's geographic strategy demonstrates a focused approach, with a significant concentration of exports in African markets. This concentration suggests a strategic emphasis on regions with growing pharmaceutical needs. The company's exploration of additional markets indicates a proactive approach to diversification and risk mitigation.

Aura Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding APPL's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export activities are primarily focused on African and Southeast Asian markets, which may not require FDA approvals.

2WHO & EU GMP

Information regarding APPL's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed. The company's focus on African and Southeast Asian markets suggests adherence to relevant international quality standards to meet regulatory requirements.

3CDSCO & Indian Regulatory

APPL holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, ensuring compliance with Indian regulatory standards. The company has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its international trade activities.

Aura Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

APPL operates in a competitive pharmaceutical industry, with numerous companies offering similar products. While specific competitors are not identified, APPL's focus on African and Southeast Asian markets positions it in competition with both local and international pharmaceutical companies targeting these regions.

2Key Differentiators

APPL's commitment to quality, competitive pricing, and adherence to international standards distinguish it in the pharmaceutical market. The company's strategic focus on emerging markets, particularly in Africa and Southeast Asia, reflects its proactive approach to growth and market expansion.

3Strategic Position

APPL's current strategic direction emphasizes the manufacturing and distribution of generic pharmaceutical formulations. The company's expansion into emerging markets indicates a focus on growth and diversification. Future outlooks suggest continued investment in quality and market expansion to strengthen its position in the global pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Aura Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

APPL's track record in the pharmaceutical industry is characterized by a commitment to quality and reliability. The company's export volume and consistency, particularly in African and Southeast Asian markets, indicate a stable and dependable supply chain. Reliability indicators include adherence to international quality standards and positive relationships with clients.

2Certifications to Verify

Importers should verify the following certifications when considering APPL as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.
WHO-GMP Certification: Ensure compliance with World Health Organization Good Manufacturing Practice standards.
EU GMP Certification: Verify adherence to European Union Good Manufacturing Practice standards.

Frequently Asked Questions — Aura Pharmaceuticals Private Limited

How many pharmaceutical products does Aura Pharmaceuticals Private Limited export from India?

Aura Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ornidazole ($222.1K), Biotin ($48.6K). Total export value is $270.8K.

What is Aura Pharmaceuticals Private Limited's total pharmaceutical export value?

Aura Pharmaceuticals Private Limited's total pharmaceutical export value is $270.8K, based on 19 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Aura Pharmaceuticals Private Limited cover?

Aura Pharmaceuticals Private Limited exports across 2 therapeutic categories. The largest are Advanced Antibiotics (82.0%, 1 products), Vitamins & Supplements (18.0%, 1 products).

Get Full Aura Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.